TheProfitWatch

BCAB - BioAtla, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
0.8 0.05 (6.33%) --- --- --- 0.03 (3.16%) 0.04 (4.67%) 0.03 (3.05%) 0.03 (3.05%)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
-0.32
Diluted EPS:
-0.32
Basic P/E:
-2.6734
Diluted P/E:
-2.6734
RSI(14) 1m:
100.0
VWAP:
0.86
RVol:

Events

Period Kind Movement Occurred At

Related News